Related Experiment Video
Updated: Dec 21, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
BCG versus COVID-19: impact on urology
1Urology Department, Wexham Park NHS Hospital, Berkshire, UK. sayedurology@hotmail.com.
Clinical trials investigating Bacillus Calmette-Guérin (BCG) for COVID-19 may impact urology practice. Potential BCG shortages and new research avenues warrant attention from urologists regarding this vaccine.
Area of Science:
- Immunology
- Infectious Diseases
- Urology
Background:
- Bacillus Calmette-Guérin (BCG) is an established vaccine with known immunomodulatory effects.
- Epidemiological studies suggest a potential role for BCG in combating SARS-CoV-2 infections.
Purpose of the Study:
- To review the evidence supporting the use of BCG in COVID-19 clinical trials.
- To assess the potential implications of these trials on urology practice.
Main Methods:
- Literature review of ongoing clinical trials involving BCG for COVID-19.
- Analysis of BCG's current use in urology and potential practice impacts.
Main Results:
- Current clinical trials are exploring BCG as a prophylactic vaccine against SARS-CoV-2.
- These trials could exacerbate the existing global BCG shortage.
- Positive trial outcomes may stimulate research into intra-vesical BCG's protective effects in urological patients.
Conclusions:
- Ongoing BCG trials for COVID-19 present potential challenges and opportunities for urology.
- Urologists must remain informed about BCG supply issues and emerging research possibilities.
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi I: Introduction
Urinary Tract Infection II: Pathophysiology
Urologic Endoscopic Procedure: Cystoscopic Examination

